Innovation for Cellular Therapies

About Vycellix™, Inc.:

Headquartered on the campus of the Moffitt Cancer Center, Tampa, Florida, Vycellix, Inc., is a closely-held immunotherapy-focused, discovery company with the mission to fundamentally impact the challenges that currently prevail in the area of cell & gene based-therapies. The Company is engaged in the development of proprietary approaches for cell-based immunotherapeutic products and to improve patient outcomes.

Vycellix’s scientific discoveries coupled with a portfolio of small molecule & RNA modulators address current limitations for cell & gene therapies, including the need to accelerate speed of production, lower costs, ensure end-cell viability and persistence, and improve patient outcomes. The Company’s innovative solutions offer the potential to significantly optimize processes for: cell reprogramming; enhancing cell potency; and improving cell expansion. Additionally, the Company is leveraging its assets to develop an early-stage pipeline of multifaceted, next-generation NK cell therapies targeting hematological malignancies and solid tumors, including its ReOpt-NK™ (Retargeted Optimized NK cell) therapy.

The Company’s products were all discovered by scientists at the world renowned Karolinska Institutet (KI) in Stockholm, Sweden. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.

Comments are closed.